Dewpoint Therapeutics has signed its second biopharma partnership, teaming up with Merck to explore the potential of using its discoveries around “droplets” of biomolecules that form inside cells to create a new HIV treatment. The companies’ aim is an ambitious one: develop a drug candidate that could prove curative, rather than suppress the infection as … Continue reading “Dewpoint, Merck Team Up to Tackle HIV Using Condensate Know-How”
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
After Biologic COVID-19 Drug OK’d in India, Equillium Plans a US Test
The drug that Equillium licensed from India-based pharma giant Biocon has received authorization for emergency use in that country in patients hospitalized with COVID-19. The treatment, itolizumab, reduced mortality in a 30-person open-label randomized controlled trial in which the goal was to avoid or address a dangerous inflammatory response to the virus called cytokine release … Continue reading “After Biologic COVID-19 Drug OK’d in India, Equillium Plans a US Test”
Turning Point Names Centrexion’s Partridge as Chief Commercial Officer
Turning Point Therapeutics (NASDAQ: [[ticker:TPTX]]) appointed Andrew Partridge as executive vice president and chief commercial officer. Partridge most recently served as chief operating officer and CCO at privately held Centrexion Therapeutics, a Boston company developing treatments for chronic pain. Previously he was with Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]), where he ended a five-year stint as senior … Continue reading “Turning Point Names Centrexion’s Partridge as Chief Commercial Officer”
Amgen Doubles Down on BeiGene Collaboration, Investing $421M More
At the year’s start Thousand Oaks, CA-based Amgen closed a strategic collaboration with BeiGene, investing $2.8 billion to gain a presence in what’s becoming an ever-more essential market for global drug development. The investment earned it an R&D pact and ownership of about one-fifth of the Chinese oncology drug company. Now the firm has snapped … Continue reading “Amgen Doubles Down on BeiGene Collaboration, Investing $421M More”
3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments
Three biotech companies collectively raised $584 million in their initial public offerings last week, continuing a streak that has the healthcare sector playing a leading role in the robust level of market activity this summer. Of the three companies, the one with investigational therapies that haven’t yet begun tests in humans raised the most. South … Continue reading “3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments”
ViaCyte Taps Insulet’s Bradrick as Its First Chief Financial Officer
ViaCyte added its first chief financial officer to its C-suite, bringing on Brittany Bradrick from Massachusetts-based medical device company Insulet (NASDAQ: [[ticker:PODD]]) where she served as vice president of strategy and corporate development. Bradrick’s prior experience includes roles in the diabetes care division at Abbott (NYSE: [[ticker:ABT]]). Before entering the industry she spent about a … Continue reading “ViaCyte Taps Insulet’s Bradrick as Its First Chief Financial Officer”
Kiadis Pharma Brings On e-Therapeutics’ Barlow as Chief Business Officer
Dutch biotech Kiadis Pharma appointed Ray Barlow as chief business officer. Barlow most recently led UK-based data-driven drug discovery company E-therapeutics as its CEO. His prior roles include serving at Amgen (NASDAQ: [[ticker:AMGN]]) as executive director of corporate development and at Crucell Vaccines, a Netherlands-based company that’s now a subsidiary of Johnson & Johnson (NASDAQ: … Continue reading “Kiadis Pharma Brings On e-Therapeutics’ Barlow as Chief Business Officer”
Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma
Rare disease drug developer Ovid Therapeutics is slated to reveal Phase 3 data from its lead program, a potential treatment for Angelman syndrome, by year’s end. If the drug is approved, the privately held Italian company Angelini Pharma will carry it forward for that indication in the Europe Union and a handful of other countries. … Continue reading “Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma”
Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More
Cash flowed throughout the life sciences ecosystem this week as Blackstone (NYSE: [[ticker:BX]]) raised a record-setting life sciences fund, companies of all stages announced new financings, and money continued to find its way to those working on efforts to treat or prevent COVID-19. Financiers poured $100 million or more into at least three biotechs, a … Continue reading “Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More”
Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership
Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based company’s research into protein degradation, the natural mechanism cells use to get rid of unwanted proteins. Drug developers are eager to leverage that cellular recycling system to create new treatments because it … Continue reading “Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership”
Cend Therapeutics Names Viracta’s David Slack As Its New President & CEO
Cancer drug developer Cend Therapeutics has appointed one of its board members, David Slack, to succeed Erkki Ruoslahti as its president and CEO. Slack, who joined the Cend board last year, was most recently chief business officer at Viracta Therapeutics. His previous experience includes serving as co-founding CEO at Kinagen and vice president for business … Continue reading “Cend Therapeutics Names Viracta’s David Slack As Its New President & CEO”
Kinnate Adds WuXi NextCODE’s Richard Williams as Chief Medical Officer
Kinnate Biopharma appointed Richard Williams as its chief medical officer. Williams was most recently CMO and global head of oncology programs at WuXi NextCODE. His prior experience includes roles with cancer detection company Grail, Amgen (NASDAQ: [[ticker:AMGN]]), and Puma Biotechnology (NASDAQ: [[ticker:PBYI]]). San Diego-based Kinnate is developing kinase inhibitors to treat genetically defined cancers.
VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs
Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company’s goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a … Continue reading “VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs”
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing
By early September Biogen—plus the many scientists, patients, and investors following the saga of its controversial Alzheimer’s drug aducanamab—should know whether the FDA plans to review the Cambridge, MA biotech’s experimental brain disease treatment. The company announced Wednesday that its submission to the FDA, pieces of which it has been submitting on a rolling basis, … Continue reading “Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing”
Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck
One way that a cell regulates which genes in its DNA are expressed and when is by altering the structure of the fibers that are formed by the genetic material and associated proteins, packaging that’s referred to as chromatin. Foghorn Therapeutics, which emerged in 2018 with plans to discover and develop new cancer drugs by … Continue reading “Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck”
Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine
The federal government’s Operation Warp Speed has made its biggest financing award yet, promising $1.6 billion to a Maryland biotech to help advance its investigational COVID-19 vaccine and ready millions of doses in preparation for its possible success. Gaithersburg, MD-based Novavax, which has never before brought a product to market, announced the federal award Tuesday. … Continue reading “Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine”
Cyteir Adds Chief Scientific Officer & Chief Business Officer to C-Suite
Cyteir Therapeutics, a developer of “synthetically lethal” drugs that tap into genetic interactions that lead to the death of cancer cells, has brought aboard two more top executives. The Lexington, MA-based company, which spun out of The Jackson Laboratory in 2012, added Paul Secrist as its chief scientific officer. Most recently Secrist was the senior … Continue reading “Cyteir Adds Chief Scientific Officer & Chief Business Officer to C-Suite”
Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs
Targeted therapies for treating cancer are designed to attack one or more proteins known to be on the surface of cancerous cells—but they don’t discriminate when they come across healthy cells expressing those same proteins. Vor Biopharma, an oncology company launched by Boston biotech PureTech Health in 2016, has raised $110 million in private financing … Continue reading “Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs”
On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO
The same week Annexon Biosciences announced it had raised $100 million in private financing to advance its research of antibody drugs to treat neurodegeneration, the company filed paperwork with regulators indicating its intention to tap the public markets, too. The South San Francisco-based company has two clinical-stage product candidates, both of which are designed to … Continue reading “On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO”
MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy
MEI Pharma and its Swiss partner Helsinn are ending a Phase 3 study of an investigational cancer drug for patients with acute myeloid leukemia (AML) after an interim analysis indicated it was unlikely to meet the trial’s main goal of helping patients live longer. San Diego-based MEI (NASDAQ: [[ticker:MEIP]]), licensed the compound, pracinostat, from a … Continue reading “MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy”
Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration
Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing its preclinical pipeline. The South San Francisco-based company is developing drugs for patients with autoimmune and neurodegenerative disorders that are caused by an abnormal … Continue reading “Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration”
Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs
Ten months ago Randy Schatzman was appointed CEO of cancer drug developer Bolt Biotherapeutics, and tasked with getting its first drug candidate into the clinic, building out its C-suite, and raising more money. On Wednesday Schatzman checked the last box on that priority list, closing a $93.5 million Series C financing round from a group … Continue reading “Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs”
Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases
The blood-brain barrier protects the functioning of that essential organ, but it’s also a hurdle to delivering neurological drugs. Italy’s Chiesi Group has agreed to pay Guilford, CT-based Bioasis Technologies $3 million up front to use the preclinical firm’s technology to facilitate the delivery of enzymes across the blood-brain barrier to treat neurological symptoms associated … Continue reading “Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases”
Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage
A growing population of people with software experience plus an interest in life sciences is boosting drug development in the San Francisco Bay Area, according to panelists at an Xcelerating event. Innovation in the San Francisco Bay Area may first bring to mind tech behemoths like Facebook and Google. But some drug development companies in … Continue reading “Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage”
Roche Gets FDA OK for Injectable Version of Breast Cancer Drug
A new version of a combination drug marketed by Roche for early-stage and metastatic breast cancer with a specific genetic signature received FDA approval Monday for a formulation that can be delivered in minutes rather than an hour or more. The antibody combo, delivered alongside IV chemotherapy, is intended for women with breast cancer that … Continue reading “Roche Gets FDA OK for Injectable Version of Breast Cancer Drug”
FDA Again Dings Heron’s Opioid Alternative Over “Nonclinical Issues”
Heron Therapeutics revealed Monday that its investigational non-opioid drug for treating postoperative pain has again been rejected by the FDA. The San Diego company’s HTX-011 is an extended-release solution of bupivacaine, a local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug. Heron (NASDAQ: [[ticker:HRTX]]) positioned it as a pain management option that could contribute to a … Continue reading “FDA Again Dings Heron’s Opioid Alternative Over “Nonclinical Issues””
With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash
DBV Technologies still expects to receive an FDA decision in early August for its peanut allergy patch. But on Friday the company, which is headquartered in the southern outskirts of Paris, said it would start layoffs and scale down its drug development activities to save cash in case the radio silence it says it has … Continue reading “With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash”
Artiva Bio Raises $78M to Broaden Access to Cancer Cell Therapies
Creating cell therapies for cancer is a complex process. The business case for them has proven tricky, too. Biotech veterans Tom Farrell and Peter Flynn have teamed up to start a new San Diego company that aims to develop allogeneic, or off-the-shelf, cell-based immunotherapies using natural killer (NK) cells that can be manufactured at scale … Continue reading “Artiva Bio Raises $78M to Broaden Access to Cancer Cell Therapies”
Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More
Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside of that arena continued apace. Once considered all but shuttered, the IPO market again saw an active week between new public debuts and more companies joining the queue. Indeed, … Continue reading “Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More”
Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs
Sophisticated computational tools have guided Relay Therapeutics in its efforts to develop new drugs based on analysis of the movement and shape of disease-causing proteins. Now the Cambridge, MA, biotech is looking to tap the public markets to bulk up company coffers and get its two lead drug candidates into mid-stage clinical trials as potential … Continue reading “Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs”
Reneo Readies for Global Test of Drug for Rare Mitochondrial Disease
Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now designing a large global study of its drug candidate. Headed by president and CEO Niall O’Donnell (pictured), the San Diego-based company launched last year … Continue reading “Reneo Readies for Global Test of Drug for Rare Mitochondrial Disease”
Gilead Grabs Option to Acquire Pionyr & Its Clinic-Bound Immunotherapies
Effective checkpoint inhibitors facilitate immune cells’ ability to recognize and target tumors. But for some patients this approach to treating cancer doesn’t work. Pionyr Immunotherapeutics aims to help those people by developing antibody drugs that take a new approach toward boosting the body’s anti-tumor efforts. Now, as Pionyr prepares to ask the FDA to clear … Continue reading “Gilead Grabs Option to Acquire Pionyr & Its Clinic-Bound Immunotherapies”
Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds
Tiny, naturally occurring particles called exosomes shuffle molecular payloads between cells, facilitating intercellular communication. Codiak Biosciences’ focus is using those nanoparticles to more safely deliver a range of medicines to specific cell types. Now the Cambridge, MA-based biotech has teamed up with neuromuscular disease drug developer Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) to explore using its engineered … Continue reading “Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds”
Timing Is an Essential Element of Cell & Gene Therapy Product Development
The science underpinning the latest investigational cell and gene therapies is complex enough. But the rapid advance of technologies that support development of these kinds of drugs presents logistical considerations, too. “Drug development is an interesting process because it takes five to 10 years to get a drug to market and invariably, somewhere along that … Continue reading “Timing Is an Essential Element of Cell & Gene Therapy Product Development”
In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo
Ten years ago Mark Smith was at MIT doing basic research into the microbiome. Now, as CEO of Finch Therapeutics Group, Smith has hard data to back up his company’s thesis that using “good” bacteria as a therapeutic can best a placebo when it comes to at least one condition: a recurrent C. difficile infection. … Continue reading “In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo”
Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs
Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential therapies. Engrail Therapeutics, which emerged from stealth Thursday with $32 million in outside financing, landed its entire Series A funding from a sole source: Nan Fung Life Sciences, a subsidiary of … Continue reading “Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs”
Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer
Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 million in Series A financing. The San Diego-based company says it will use the money to accelerate its antibody programs, including asking the FDA for the green light to move its lead drug candidate … Continue reading “Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer”
C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic
C4 Therapeutics, a biotech developing small molecules designed to take advantage of a cellular mechanism as a way to treat disease, has raised $170 million in venture equity and debt to start human testing. The Watertown, MA-based firm is among a number of companies competing in the popular protein degradation space, in which drug developers … Continue reading “C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic”
Kaleido Bio CEO Lawton Resigns; Company Plans Search for Successor
Kaleido Biosciences (NASDAQ: [[ticker:KLDO]]) president and CEO Alison Lawton stepped down on Tuesday to “attend to an unexpected family health matter,” the microbiome therapies developer said. Lawton joined Kaledio in December 2017 as president and chief operating officer. She was promoted to chief executive in August 2018. The Lexington, MA-based biotech, a Flagship Pioneering spinout, … Continue reading “Kaleido Bio CEO Lawton Resigns; Company Plans Search for Successor”
Exec Search Underway at PacBio After CEO, CFO Announce Plans to Retire
Gene sequencing company Pacific Biosciences of California is seeking two new leaders in the wake of retirement announcements by a pair of longtime top executives. PacBio (NASDAQ: [[ticker:PACB]]) president and CEO Michael Hunkapiller plans to retire by year’s end, and the company’s chief financial officer, Susan Barnes, is slated to do the same in August. … Continue reading “Exec Search Underway at PacBio After CEO, CFO Announce Plans to Retire”
Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug
The FDA on Monday approved a new drug for patients with advanced small cell lung cancer, permitting the treatment to be marketed based on less evidence than it traditionally requires in order to speed its path to market. Madrid-based PharmaMar, which developed lurbinectedin (Zepzelca), licensed its US commercialization rights to Jazz Pharmaceuticals (NASDAQ: [[ticker:JAZZ]]) last … Continue reading “Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug”
FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19
The FDA on Monday revoked its emergency authorization permitting use of the antimalarial drugs hydroxychloroquine and chloroquine to treat the novel coronavirus, citing a lack of evidence of their efficacy. In late March the agency authorized the drugs, which President Donald Trump touts often as a potential treatment, for patients who were hospitalized with COVID-19 … Continue reading “FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19”
Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment
One year after the FDA approved the first-ever treatment for a rare autoimmune condition that primarily affects the optic nerves and spinal cord, the agency has approved the second. That second regulatory nod goes to Viela Bio (NASDAQ: [[ticker:VIE]]) drug inebilizumab (Uplizna) for adults with neuromyelitis optica spectrum disorder (NMOSD) who also have a particular … Continue reading “Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment”
Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More
At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the … Continue reading “Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More”
Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA
Reata Pharmaceuticals is readying its lead drug, a potential treatment for a rare, genetic form of chronic kidney disease called Alport syndrome, for an FDA filing this year. New York private equity giant Blackstone Group, via its newly flush life sciences investment arm, is betting $350 million that the treatment will be a big seller … Continue reading “Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA”
AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal
In one of the largest oncology partnerships ever, AbbVie and Genmab are teaming up to accelerate development and commercialization of three of the Danish biotech’s investigational bispecific antibody drugs and potentially develop more. North Chicago, IL-based AbbVie (NYSE: [[ticker:ABBV]]) is spending $750 million up front to kick off the effort, which involves two clinical-stage drugs, … Continue reading “AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal”
Fauci Foresees “More Than 1 Winner” in Race for COVID-19 Vaccines, Drugs
To ameliorate a pandemic that infectious disease expert Anthony Fauci calls his “worst nightmare,” a winner-takes-all solution won’t be enough. Fauci, who directs the National Institute of Allergy and Infectious Diseases, this week told attendees at the Biotechnology Innovation Organization’s annual convention that developing multiple vaccines and therapeutics will be necessary to tamp down the … Continue reading “Fauci Foresees “More Than 1 Winner” in Race for COVID-19 Vaccines, Drugs”
Iteos Therapeutics Taps Sarepta’s Gall as Chief Financial Officer
Cancer drug developer Iteos Therapeutics announced Tuesday that it appointed Matthew Gall as its chief financial officer. Gall was most recently senior vice president of corporate development and treasurer at Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]). His previous experience includes roles at Celgene and Gilead Sciences (NASDAQ: [[ticker:GILD]]). Iteos, a Belgium-based firm with US headquarters in Cambridge, … Continue reading “Iteos Therapeutics Taps Sarepta’s Gall as Chief Financial Officer”
Ardelyx Taps Correvio’s Justin Renz as Its Chief Financial Officer
Justin Renz has joined Ardelyx (NASDAQ: [[ticker:ARDX]]) as chief financial officer. Renz most recently held the same role at Vancouver, BC-based Correvio Pharma, which was acquired last month by the UK company Advanz Pharma for about $76 million. His prior experience includes management roles at Karyopharm Therapeutics (NASDAQ: [[ticker:KPTI]]) and Zalicus (formerly CombinatoRx). Fremont, CA-based … Continue reading “Ardelyx Taps Correvio’s Justin Renz as Its Chief Financial Officer”
Amplyx Appoints Mirati’s Chris LeMasters as Chief Operating Officer
Amplyx Pharmaceuticals announced Monday the addition of Chris LeMasters to its C-suite as chief operating officer. LeMasters most recently served as chief business officer at cancer drug developer Mirati Therapeutics (NASDAQ: [[ticker:MRTX]]), another San Diego-based biotech. He left Mirati in January after about three years there. His prior experience includes senior management roles at Promosome, Tragara … Continue reading “Amplyx Appoints Mirati’s Chris LeMasters as Chief Operating Officer”